263 related articles for article (PubMed ID: 33510787)
1. Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature.
Briganti SI; Naciu AM; Tabacco G; Cesareo R; Napoli N; Trimboli P; Castellana M; Manfrini S; Palermo A
Int J Endocrinol; 2021; 2021():8902367. PubMed ID: 33510787
[TBL] [Abstract][Full Text] [Related]
2. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved.
Thong BKS; Ima-Nirwana S; Chin KY
Int J Environ Res Public Health; 2019 May; 16(9):. PubMed ID: 31060319
[TBL] [Abstract][Full Text] [Related]
5. The relationship among proton pump inhibitors, bone disease and fracture.
Targownik LE; Leslie WD
Expert Opin Drug Saf; 2011 Nov; 10(6):901-12. PubMed ID: 21599546
[TBL] [Abstract][Full Text] [Related]
6. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Lau YT; Ahmed NN
Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
8. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
9. Use of Proton Pump Inhibitors and Risk of Fracture in Adults: A Review of Literature.
Paudel Y; Najam B; Desai HN; Illango J; Seffah KD; Kumar M; Naveen N; Pachchipulusu VK; Penumetcha SS
Cureus; 2023 Dec; 15(12):e49872. PubMed ID: 38170137
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.
Ngamruengphong S; Leontiadis GI; Radhi S; Dentino A; Nugent K
Am J Gastroenterol; 2011 Jul; 106(7):1209-18; quiz 1219. PubMed ID: 21483462
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
Maggio M; Lauretani F; Ceda GP; De Vita F; Bondi G; Corsonello A; Cattabiani C; Lattanzio F; Ruggiero C; Nouvenne A; Meschi T; Bandinelli S; Ferrucci L
Bone; 2013 Dec; 57(2):437-42. PubMed ID: 24076021
[TBL] [Abstract][Full Text] [Related]
12. Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review.
Edinoff AN; Wu NW; Parker K; Dudossat E; Linquest L; Flanagan CJ; Dharani A; Patel H; Willett O; Cornett EM; Kaye AM; Kaye AD
Adv Ther; 2023 Jun; 40(6):2693-2709. PubMed ID: 37140707
[TBL] [Abstract][Full Text] [Related]
13. Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Lespessailles E; Toumi H
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142643
[TBL] [Abstract][Full Text] [Related]
14. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors, bone and phosphocalcic metabolism.
Philippoteaux C; Paccou J; Chazard E; Cortet B
Joint Bone Spine; 2024 Mar; 91(5):105714. PubMed ID: 38458487
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors and fracture risk. The HUNT study, Norway.
Hoff M; Skovlund E; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Forsmo S; Abrahamsen B; Schei B
Osteoporos Int; 2020 Jan; 31(1):109-118. PubMed ID: 31741023
[TBL] [Abstract][Full Text] [Related]
17. Osseous implications of proton pump inhibitor therapy: An umbrella review.
Alanazi AS; Almutairi H; Gupta JK; Mohanty D; Rath D; AlOdan AA; Mahal A; Khatib MN; Gaidhane S; Zahiruddin QS; Rustagi S; Satapathy P; Serhan HA
Bone Rep; 2024 Mar; 20():101741. PubMed ID: 38348455
[TBL] [Abstract][Full Text] [Related]
18. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use.
Thurber KM; Otto AO; Stricker SL
Am J Health Syst Pharm; 2023 Apr; 80(8):487-494. PubMed ID: 36629265
[TBL] [Abstract][Full Text] [Related]
20. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
